This protein carries a polyhistidine tag at the C-terminus. The active form of Human PLAU is a disulfide-linked heterodimer composed of long chain A (Ser 21 - Phe 177) and chain B (Ile 179 - Leu 431) with calculated MW of 17.8 kDa and 29.2 kDa. The long chain A is further cleaved to yield a short chain A (Lys 156 - Phe 177) and N-terminal fragment (Ser 21 - Lys 155) with calculated MW of 15.3 kDa. The protein migrates as 17 kDa (N-terminal fragment), 32-35 kDa (chain B) and 45-50 kDa (long chain A & chain B) under non-reducing (NR) condition (SDS-PAGE) due to glycosylation.
>90% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in 25 mM HEPES, 150 mM NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Human PLAU, His Tag (activated by trypsin) on SDS-PAGE under non-reducing (NR) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.
Measured by it's ability to cleave a peptide substrate, N-carbobenzyloxy-Gly-Gly-Arg-7-amido-4-methylcoumarin (Z-GGR-AMC). The specific activity is >2,000 pmol/min/µg, as measured under the described conditions (QC tested).
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
Emerging VoCs, Lambda, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ELISA kits for neutralizing antibody titer assay, binding antibody titer assay, antibody isotype assay, antigen titer assay and inhibitor screening, etc., which can accelerate the research and development of anti-SARS-CoV-2 drugs and vaccines.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2， CD133, GPRC5D，CCR8, CCR5, etc.
This web search service is supported by Google Inc.